ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)

Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome. Vice versa, targeted inhibition of BRAF-V600E with the selective inhibitor PLX 4032 (Vemurafenib) is severely limited due to f...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Prasetyanti, Pramudita R., Capone, Emily, Barcaroli, Daniela, D'Agostino, Daniela, Volpe, Silvia, Benfante, Antonina, van Hooff, Sander, Iacobelli, Valentina, Rossi, Cosmo, Iacobelli, Stefano, Medema, Jan Paul, De Laurenzi, Vincenzo, Sala, Gianluca
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2015
Предметы:
Priority Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627280/
https://ncbi.nlm.nih.gov/pubmed/26160848
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы